|Written by GSCR Staff|
|Wednesday, 05 August 2015 05:46|
In Monday’s Guide we reviewed some data that showed August has not been the ‘bad’ month it is made out to be. Yesterday, MarketWatch expanded on this theme in this article.
This was an interesting article, but we will be honest here. The picture of Rodney Dangerfield is what caught our attention. I would request some of our younger readers to look some of his 70’s stand-up on YouTube. Classic!
In this week’s Guide we also mentioned the dog days of the summer with a cuddly picture of a puppy. There is no doubt people’s pets are super important to them, as people are spending money on major surgery, acupuncture and other exotic procedures to keep Fido around. Sometimes you have to wonder if it has gone too far. Surely anyone who has turned on a TV over the last week has seen the story of the slaying of Cecil the Lion in Zimbabwe by a Minnesota dentist who remains in hiding. By no means are we big game hunting advocates, but it seems this story and the public outcry was bigger than a lot of human tragedies. But we digress. We have to find a way to play this shift in values in the stock market.
PetMed Express, Inc. (NASDAQ – PETS - $16.95) is often called the “Amazon” of the pet supplies world. The Company and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The Company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes. The Company also sells food, beds, crates, stairs, strollers, and other pet supplies through its Website.
The chart below shows that PETS has been on a nice one year momentum rise and is currently trading right at the 50-day EMA.
PETS 1-Year Chart, 50-Day EMA
One item that we have been hot on recently is firm debt. As of the end of June, PetMed Express has zero debt. Financial reporting, particularly EPS has been something we view as important right now. The Company beat EPS estimates for its FYQ1 2016 reporting coming at $0.29 per shares versus the $0.28 estimate.
PETS is a solid play on the macroeconomic phenomenon of increased spending on house pets in the U.S. The stock is approaching the 52-week high of $17.15. If the stock breaks thru this resistance level it could run up to $19 this year.
Have a great day!
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.
ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com